{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:51:48Z","timestamp":1792165908624,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","award":["10.13039\/100004755"],"award-info":[{"award-number":["10.13039\/100004755"]}],"id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In multiple sclerosis (MS), persisting disability can occur independent of relapse activity or development of new central nervous system (CNS) inflammatory lesions, termed chronic progression. This process occurs early and it is mostly driven by cells within the CNS. One promising strategy to control progression of MS is the inhibition of the enzyme Bruton's tyrosine kinase (BTK), which is centrally involved in the activation of both B cells and myeloid cells, such as macrophages and microglia. The benefit of BTK inhibition by evobrutinib was shown as we observed reduced pro-inflammatory activation of microglia when treating chronic experimental autoimmune encephalomyelitis (EAE) or following the adoptive transfer of activated T\u00a0cells. Additionally, in a model of toxic demyelination, evobrutinib-mediated BTK inhibition promoted the clearance of myelin debris by microglia, leading to an accelerated remyelination. These findings highlight that BTK inhibition has the potential to counteract underlying chronic progression of MS.<\/jats:p>","DOI":"10.1007\/s00401-024-02730-0","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:01:56Z","timestamp":1713970916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair"],"prefix":"10.1007","volume":"147","author":[{"given":"Anastasia","family":"Geladaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Torke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin B.","family":"Alankus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Zechel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stadelmann-Nessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Boschert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"H\u00e4usler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-0389","authenticated-orcid":false,"given":"Martin S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"2730_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","volume":"33","author":"M Absinta","year":"2020","unstructured":"Absinta M, Lassmann H, Trapp BD (2020) Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol 33:277\u2013285. https:\/\/doi.org\/10.1097\/WCO.0000000000000818","journal-title":"Curr Opin Neurol"},{"key":"2730_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31:88\u201394. https:\/\/doi.org\/10.1200\/JCO.2012.42.7906","journal-title":"J Clin Oncol"},{"key":"2730_CR3","doi-asserted-by":"crossref","unstructured":"Arnold DL, Elliott C, Montalban X, Martin E, Hyvert Y, Tomic D (2021) Effects of evobrutinib, a Bruton\u2019s tyrosine kinase inhibitor, on slowly expanding lesions: an emerging imaging marker of chronic tissue loss in multiple sclerosis. ECTRIMS 2021:","DOI":"10.1212\/WNL.98.18_supplement.2674"},{"key":"2730_CR4","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40265-018-0984-5","volume":"78","author":"LE Baldassari","year":"2018","unstructured":"Baldassari LE, Fox RJ (2018) Therapeutic advances and challenges in the treatment of progressive multiple sclerosis. Drugs 78:1549\u20131566. https:\/\/doi.org\/10.1007\/s40265-018-0984-5","journal-title":"Drugs"},{"key":"2730_CR5","first-page":"P678","volume":"2017","author":"U Boschert","year":"2017","unstructured":"Boschert U, Crandall T, Pereira A, Higginbotham G, Wu Y, R. G, Savinainen A, Bender A, (2017) T cell mediated experimental CNS autoimmunity induced by PLP in SJL mice is modulated by Evobrutinib (M2951) a novel Bruton\u2019s tyrosine kinase inhibitor. ECTRIMS Online Library 2017:P678","journal-title":"ECTRIMS Online Library"},{"key":"2730_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7070078","author":"N Dargahi","year":"2017","unstructured":"Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J et al (2017) Multiple sclerosis: immunopathology and treatment update. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci7070078","journal-title":"Brain Sci"},{"key":"2730_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamaneurol.2022.5332","volume":"80","author":"S Dybowski","year":"2023","unstructured":"Dybowski S, Torke S, Weber MS (2023) Targeting B cells and microglia in multiple sclerosis with bruton tyrosine kinase inhibitors: a review. JAMA Neurol 80:404\u2013414. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5332","journal-title":"JAMA Neurol"},{"key":"2730_CR8","doi-asserted-by":"publisher","first-page":"1264128","DOI":"10.3389\/fimmu.2023.1264128","volume":"14","author":"ML Elkjaer","year":"2023","unstructured":"Elkjaer ML, Waede MR, Kingo C, Damsbo K, Illes Z (2023) Expression of Bruton s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Front Immunol 14:1264128. https:\/\/doi.org\/10.3389\/fimmu.2023.1264128","journal-title":"Front Immunol"},{"key":"2730_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102560","author":"A Garcia-Merino","year":"2021","unstructured":"Garcia-Merino A (2021) Bruton\u2019s tyrosine kinase inhibitors: a new generation of promising agents for multiple sclerosis therapy. Cells. https:\/\/doi.org\/10.3390\/cells10102560","journal-title":"Cells"},{"key":"2730_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073461","author":"A Geladaris","year":"2021","unstructured":"Geladaris A, H\u00e4usler D, Weber MS (2021) Microglia: the missing link to decipher and therapeutically control MS progression? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22073461","journal-title":"Int J Mol Sci"},{"key":"2730_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40263-022-00951-z","volume":"36","author":"A Geladaris","year":"2022","unstructured":"Geladaris A, Torke S, Weber MS (2022) Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis: pioneering the path towards treatment of progression? CNS Drugs 36:1019\u20131030. https:\/\/doi.org\/10.1007\/s40263-022-00951-z","journal-title":"CNS Drugs"},{"key":"2730_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.808","author":"R Gruber","year":"2020","unstructured":"Gruber R, Chretien N, Dufault M, Proto J, Zhang M, LaMorte M et al (2020) Central effects of BTK inhibition in neuroinflammation (808). Neurology. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.808","journal-title":"Neurology"},{"key":"2730_CR13","unstructured":"Gruber R, Lee L, Dufaukt R, Chretien N, Blazier A, Proto J, Zhang M, Havari E, Turner T, Chamyk Aet al (2021) Evaluating the Effect of BTK Inhibitor Tolebrutinib in Human Microglia ECTRIMS 2021"},{"issue":"1380\u20131390","key":"2730_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med 133(1380\u20131390):e1382. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049","journal-title":"Am J Med"},{"key":"2730_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fncel.2020.00198","volume":"14","author":"AM Jurga","year":"2020","unstructured":"Jurga AM, Paleczna M, Kuter KZ (2020) Overview of general and discriminating markers of differential microglia phenotypes. Front Cell Neurosci 14:198. https:\/\/doi.org\/10.3389\/fncel.2020.00198","journal-title":"Front Cell Neurosci"},{"key":"2730_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12974-022-02408-y","volume":"19","author":"E Kamma","year":"2022","unstructured":"Kamma E, Lasisi W, Libner C, Ng HS, Plemel JR (2022) Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. J Neuroinflammation 19:45. https:\/\/doi.org\/10.1186\/s12974-022-02408-y","journal-title":"J Neuroinflammation"},{"key":"2730_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11481-019-09839-0","volume":"14","author":"J Keaney","year":"2019","unstructured":"Keaney J, Gasser J, Gillet G, Scholz D, Kadiu I (2019) Inhibition of Bruton\u2019s tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer\u2019s disease. J Neuroimmune Pharmacol 14:448\u2013461. https:\/\/doi.org\/10.1007\/s11481-019-09839-0","journal-title":"J Neuroimmune Pharmacol"},{"key":"2730_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22:78\u201388. https:\/\/doi.org\/10.1016\/S1474-4422(22)00289-7","journal-title":"Lancet Neurol"},{"key":"2730_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","volume":"133","author":"H Lassmann","year":"2017","unstructured":"Lassmann H, Bradl M (2017) Multiple sclerosis: experimental models and reality. Acta Neuropathol 133:223\u2013244. https:\/\/doi.org\/10.1007\/s00401-016-1631-4","journal-title":"Acta Neuropathol"},{"key":"2730_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","volume":"180","author":"H Link","year":"2006","unstructured":"Link H, Huang YM (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180:17\u201328. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.07.006","journal-title":"J Neuroimmunol"},{"key":"2730_CR21","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J et al (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147\u20133161. https:\/\/doi.org\/10.1093\/brain\/awac016","journal-title":"Brain"},{"key":"2730_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.neurol.2018.01.370","volume":"174","author":"E Maillart","year":"2018","unstructured":"Maillart E (2018) Treatment of progressive multiple sclerosis: Challenges and promising perspectives. Rev Neurol (Paris) 174:441\u2013448. https:\/\/doi.org\/10.1016\/j.neurol.2018.01.370","journal-title":"Rev Neurol (Paris)"},{"key":"2730_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/BPL-200100","volume":"5","author":"E Martin","year":"2020","unstructured":"Martin E, Aigrot MS, Grenningloh R, Stankoff B, Lubetzki C, Boschert U et al (2020) Bruton\u2019s tyrosine kinase inhibition promotes myelin repair. Brain Plast 5:123\u2013133. https:\/\/doi.org\/10.3233\/BPL-200100","journal-title":"Brain Plast"},{"key":"2730_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0165-5728(02)00205-9","volume":"130","author":"EJ McMahon","year":"2002","unstructured":"McMahon EJ, Suzuki K, Matsushima GK (2002) Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 130:32\u201345. https:\/\/doi.org\/10.1016\/s0165-5728(02)00205-9","journal-title":"J Neuroimmunol"},{"key":"2730_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jns.2008.06.032","volume":"274","author":"E Meinl","year":"2008","unstructured":"Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R (2008) Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci 274:42\u201344. https:\/\/doi.org\/10.1016\/j.jns.2008.06.032","journal-title":"J Neurol Sci"},{"key":"2730_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.844873","volume":"13","author":"M Mirabella","year":"2022","unstructured":"Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C (2022) Treatment challenges in multiple sclerosis - a continued role for glatiramer acetate? Front Neurol 13:844873. https:\/\/doi.org\/10.3389\/fneur.2022.844873","journal-title":"Front Neurol"},{"key":"2730_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231846","volume":"15","author":"C Ohlmeier","year":"2020","unstructured":"Ohlmeier C, Gothe H, Haas J, Osowski U, Weinhold C, Blauwitz S et al (2020) Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS ONE 15:e0231846. https:\/\/doi.org\/10.1371\/journal.pone.0231846","journal-title":"PLoS ONE"},{"key":"2730_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12017-009-8099-5","volume":"12","author":"E Okun","year":"2010","unstructured":"Okun E, Mattson MP, Arumugam TV (2010) Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med 12:164\u2013178. https:\/\/doi.org\/10.1007\/s12017-009-8099-5","journal-title":"Neuromolecular Med"},{"key":"2730_CR29","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1111\/cts.13407","volume":"15","author":"O Papasouliotis","year":"2022","unstructured":"Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M (2022) Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study. Clin Transl Sci 15:2888\u20132898. https:\/\/doi.org\/10.1111\/cts.13407","journal-title":"Clin Transl Sci"},{"key":"2730_CR30","doi-asserted-by":"crossref","unstructured":"Piasecka-Stryczynska K, Rejdak K, Dyroff M, Hyvert Y, Holmberg K, Mandel M, Cunha C, Mitchell D, Martin E, Montalban X (2021) Concentration of evobrutinib, a BTK inhibitor, in cerebrospinal fluid during treatment of patients with relapsing multiple sclerosis in a phase 2 study. Multiple Sclerosis and Related Disorders 51:","DOI":"10.1016\/j.msard.2021.103001"},{"key":"2730_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40478-020-0885-1","volume":"8","author":"S Rodriguez-Lorenzo","year":"2020","unstructured":"Rodriguez-Lorenzo S, Konings J, van der Pol S, Kamermans A, Amor S, van Horssen J et al (2020) Inflammation of the choroid plexus in progressive multiple sclerosis: accumulation of granulocytes and T cells. Acta Neuropathol Commun 8:9. https:\/\/doi.org\/10.1186\/s40478-020-0885-1","journal-title":"Acta Neuropathol Commun"},{"key":"2730_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2008.070850","volume":"172","author":"T Skripuletz","year":"2008","unstructured":"Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F et al (2008) Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172:1053\u20131061. https:\/\/doi.org\/10.2353\/ajpath.2008.070850","journal-title":"Am J Pathol"},{"key":"2730_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrneurol.2013.41","volume":"9","author":"M Stangel","year":"2013","unstructured":"Stangel M, Fredrikson S, Meinl E, Petzold A, Stuve O, Tumani H (2013) The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 9:267\u2013276. https:\/\/doi.org\/10.1038\/nrneurol.2013.41","journal-title":"Nat Rev Neurol"},{"key":"2730_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","volume":"140","author":"S Torke","year":"2020","unstructured":"Torke S, Pretzsch R, Hausler D, Haselmayer P, Grenningloh R, Boschert U et al (2020) Inhibition of Bruton\u2019s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol 140:535\u2013548. https:\/\/doi.org\/10.1007\/s00401-020-02204-z","journal-title":"Acta Neuropathol"},{"key":"2730_CR35","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/13543784.2020.1807934","volume":"29","author":"S Torke","year":"2020","unstructured":"Torke S, Weber MS (2020) Inhibition of Bruton s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opin Investig Drugs 29:1143\u20131150. https:\/\/doi.org\/10.1080\/13543784.2020.1807934","journal-title":"Expert Opin Investig Drugs"},{"key":"2730_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0022-510X(94)90340-9","volume":"121","author":"E Ulvestad","year":"1994","unstructured":"Ulvestad E, Williams K, Vedeler C, Antel J, Nyland H, M\u00f8rk S et al (1994) Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 121:125\u2013131","journal-title":"J Neurol Sci"},{"key":"2730_CR37","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.4049\/jimmunol.2000130","volume":"205","author":"M van der Poel","year":"2020","unstructured":"van der Poel M, Hoepel W, Hamann J, Huitinga I, Dunnen JD (2020) IgG immune complexes break immune tolerance of human microglia. J Immunol 205:2511\u20132518. https:\/\/doi.org\/10.4049\/jimmunol.2000130","journal-title":"J Immunol"},{"key":"2730_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jnr.10368","volume":"70","author":"X Yuan","year":"2002","unstructured":"Yuan X, Chittajallu R, Belachew S, Anderson S, McBain CJ, Gallo V (2002) Expression of the green fluorescent protein in the oligodendrocyte lineage: a transgenic mouse for developmental and physiological studies. J Neurosci Res 70:529\u2013545. https:\/\/doi.org\/10.1002\/jnr.10368","journal-title":"J Neurosci Res"},{"key":"2730_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13024-022-00538-8","volume":"17","author":"M Zirngibl","year":"2022","unstructured":"Zirngibl M, Assinck P, Sizov A, Caprariello AV, Plemel JR (2022) Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener 17:34. https:\/\/doi.org\/10.1186\/s13024-022-00538-8","journal-title":"Mol Neurodegener"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-024-02730-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:04:51Z","timestamp":1713971091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-024-02730-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1007\/s00401-024-02730-0","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.S.W. received travel funding and\/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer, and Genzyme. S.T. received travel funding from Merck Serono. U.B. is an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt Germany. Y.B.A is an employee of EMD Serono. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"75"}}